TriangleNCT03483103 · OUTCOME
Change From Baseline of Chemistry Laboratory Results: Alanine Aminotransferase, Aspartate Aminotransferase, Lactate Dehydrogenase
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- U/L
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline and Day 29
What was measured
Change from baseline in Chemistry laboratory analysis. Includes Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase. Baseline is the last observation collected prior to or on the date of product infusion.
Analysis population: All participants who received at least one JCAR017 infusion evaluable for chemistry laboratory tests
Groups in this outcome
Lisocabtagene Maraleucel (JCAR017)
Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.
| Group | Source count |
|---|---|
| Lisocabtagene Maraleucel (JCAR017) | 59 |
Reported measurements
Alanine Aminotransferase
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Lisocabtagene Maraleucel (JCAR017) | 4.6 | 16.42 | Not reported | Not reported | Not reported |
Aspartate Aminotransferase
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Lisocabtagene Maraleucel (JCAR017) | -3.9 | 21.22 | Not reported | Not reported | Not reported |
Lactate Dehydrogenase
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Lisocabtagene Maraleucel (JCAR017) | -138.2 | 339.82 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 16.42
- value
- 4.6
- title
- Alanine Aminotransferase
- categories
- measurements
- group Id
- OG000
- spread
- 21.22
- value
- -3.9
- title
- Aspartate Aminotransferase
- categories
- measurements
- group Id
- OG000
- spread
- 339.82
- value
- -138.2
- title
- Lactate Dehydrogenase
- denoms
- counts
- group Id
- OG000
- value
- 59
- units
- Participants
- description
- Change from baseline in Chemistry laboratory analysis. Includes Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase. Baseline is the last observation collected prior to or on the date of product infusion.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.
- id
- OG000
- title
- Lisocabtagene Maraleucel (JCAR017)
- param Type
- MEAN
- population Description
- All participants who received at least one JCAR017 infusion evaluable for chemistry laboratory tests
- reporting Status
- POSTED
- time Frame
- Baseline and Day 29
- title
- Change From Baseline of Chemistry Laboratory Results: Alanine Aminotransferase, Aspartate Aminotransferase, Lactate Dehydrogenase
- type
- SECONDARY
- unit Of Measure
- U/L
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice